Journal
CANCER
Volume 124, Issue 13, Pages 2693-2703Publisher
WILEY
DOI: 10.1002/cncr.31284
Keywords
barriers; challenges; outcomes; success; therapy; treatment; trials; uveal melanoma
Categories
Funding
- National Institutes of Health [P30CA016672]
- National Institutes of Health Cancer Center Support [P30CA082103]
Ask authors/readers for more resources
The rate of advances in uveal melanoma has not kept pace with the rate of advances in cutaneous melanoma. Many patients lack access to or knowledge of specialty centers, and integrated multidisciplinary care between ophthalmology, radiation oncology, and medical oncology is far from the norm. This treatment isolation leads to limited communication about novel clinical trial opportunities. Clinical trials themselves are not widely available, and a lack of robust funding limits rapid and complete investigations. This review outlines the obstacles to success in uveal melanoma management and highlights strategies for overcoming these challenges. (C) 2018 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available